Target Expression –
Understanding how a therapeutic candidate may impact different tissues/organ systems throughout the human body following target engagement can help to make more informed development decisions. Using a set of 72 non-diseased human tissues and a validated quantitative reverse transcription-polymerase chain reaction (qRT-PCR) methodology to profile gene expression, Precision has developed XpressWay Profiles, a robust, quantitative platform to provide insight into whole body target expression. Our established XpressWay Profile database contains profiles for more than 2,300 genes, which enables immediate access to robust data for your target(s) of interest. In addition, we can rapidly generate these data profiles for new targets and/or variants on demand.
Capabilities and Advantages of XpressWay Profiles for Target Expression
Our established XpressWay Profile database contains profiles for more than 2,300 genes, which enables immediate access to robust data for your target(s) of interest. In addition, we can rapidly generate these data profiles for new targets and/or variants on demand.
- Target validation
- Safety liability
- Drug repurposing
- Validation of animal models
- qRT-PCR based for sensitive and quantitative expression data
- Validated and robust methodology
- Existing profiles can be leveraged for rapid data delivery, or new profiles can be generated
Tissue and Profile Details
- Data are generated using 72 non-diseased tissues representing all core organ systems, each tissue from n=3 independent donors
- 2,300 existing gene profiles available
Integrating biomarker and clinical trial data
To help researchers understand and interpret biomarker assay data in the context of other assays as well as the clinical trial data, Precision manages all assay data using our proprietary QuartzBio Translational Informatics platform.
Learn more about the sample management, informatics, and computational capabilities of QuartzBio.
Global Reach, Multi-site Support
We provide target and biomarker validation services that support pre-clinical research conducted anywhere in the world.
Working with Precision
Precision’s specialty lab scientists take a collaborative and consultative approach to projects and can provide recommendations on biomarker assay strategies and implementation. Services can be provided individually or as part of a comprehensive therapeutic development package including biomarker assays and clinical trials.
Precision’s immunohistochemistry (IHC) services can be customized based on study needs, and can include development of logistical processes, kitting, special stains, and creation of a custom assay and scoring system.
Our in-house pathology team can provide expert assessments with rapid turn-around times, and has a full suite of sample processing services including formalin-fixed, paraffin-embedded (FFPE) and microdissection for genomics applications.
We offer automated multiplex immunofluorescence (mIF) services that enable quantitative visualization of as many as 9 markers in tissue and liquid biopsies, and individual cells. mIF can be integrated with other methods including co-analysis using fluorescent in situ hybridization/in situ hybridization (FISH/ISH).